SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-8.88%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$568M
AUM Growth
+$568M
(-15%)
Cap. Flow
-$10.3M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
41.82%
Holding
155
New
29
Increased
27
Reduced
41
Closed
33
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$32.5M |
| 2 |
Elbit Systems
ESLT
|
$29.2M |
| 3 |
Incyte
INCY
|
$11M |
| 4 |
CEL
Cellcom Israel, Ltd.
CEL
|
$8.79M |
| 5 |
Biogen
BIIB
|
$7.08M |
Top Sells
| 1 |
Merck
MRK
|
$22.8M |
| 2 |
Gilead Sciences
GILD
|
$19.6M |
| 3 |
Pfizer
PFE
|
$9.42M |
| 4 |
CXRX
Concordia International Corp. Common Stock
CXRX
|
$9.03M |
| 5 |
Verint Systems
VRNT
|
$8.47M |
Sector Composition
| 1 | Healthcare | 76.98% |
| 2 | Industrials | 5.61% |
| 3 | Utilities | 3.5% |
| 4 | Technology | 1.75% |
| 5 | Consumer Discretionary | 1.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ellomay Capital Ltd
ELLO
$239M
| $2.34M | 0.3% | 221,097 -25,600 | -10% | -$270K |
|
77
SCYNEXIS
SCYX
$34.9M
| $2.28M | 0.29% | 313,000 | – | – |
|
|
ATYR
78
aTyr Pharma
ATYR
$527M
| $2.15M | 0.27% | 209,027 | – | – |
|
79
Summit Therapeutics
SMMT
$17.6B
| $2.14M | 0.27% | 205,200 | – | – |
|
|
CEMP
80
DELISTED
Cempra, Inc.
CEMP
| $2.09M | 0.27% | +75,000 | New | +$2.09M |
|
|
IMDZ
81
DELISTED
Immune Design Corp.
IMDZ
| $2.07M | 0.26% | 170,000 +30,000 | +21% | +$366K |
|
82
Prothena Corp
PRTA
$441M
| $2.05M | 0.26% | 45,133 -70,000 | -61% | -$3.17M |
|
|
AEGR
83
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $2.04M | 0.26% | +150,000 | New | +$2.04M |
|
84
Halozyme
HALO
$8.56B
| $2.02M | 0.26% | 150,000 | – | – |
|
85
Wabtec
WAB
$33.1B
| $2M | 0.26% | 22,735 +370 | +2% | +$32.6K |
|
|
RLYP
86
DELISTED
RELYPSA INC COM
RLYP
| $1.98M | 0.25% | 107,000 -25,000 | -19% | -$463K |
|
|
EPZM
87
DELISTED
Epizyme, Inc
EPZM
| $1.93M | 0.25% | +150,000 | New | +$1.93M |
|
|
SGEN
88
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.93M | 0.25% | 50,000 -90,000 | -64% | -$3.47M |
|
|
TRIL
89
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.92M | 0.24% | 147,000 | – | – |
|
90
Novartis
NVS
$245B
| $1.84M | 0.23% | 20,000 -80,000 | -80% | -$7.35M |
|
91
Sarepta Therapeutics
SRPT
$1.78B
| $1.77M | 0.23% | 55,000 -95,000 | -63% | -$3.05M |
|
|
NDRM
92
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.76M | 0.22% | +85,000 | New | +$1.76M |
|
93
Palo Alto Networks
PANW
$127B
| $1.72M | 0.22% | +10,002 | New | +$1.72M |
|
|
NBRV
94
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $1.66M | 0.21% | +175,000 | New | +$1.66M |
|
|
PVLA
95
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $1.65M | 0.21% | 900,000 -300,000 | -25% | -$549K |
|
|
ZGNX
96
DELISTED
Zogenix, Inc.
ZGNX
| $1.62M | 0.21% | +120,000 | New | +$1.62M |
|
|
ARRY
97
DELISTED
Array Biopharma Inc
ARRY
| $1.6M | 0.2% | 350,000 -450,000 | -56% | -$2.05M |
|
|
OCRX
98
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $1.58M | 0.2% | +500,000 | New | +$1.58M |
|
99
Aldeyra Therapeutics
ALDX
$351M
| $1.55M | 0.2% | 265,000 | – | – |
|
100
KalVista Pharmaceuticals
KALV
$678M
| $1.43M | 0.18% | 400,000 | – | – |
|